About Q2 Solutions
Q2 Solutions is a global clinical trial laboratory services organization that helps customers achieve better clinical trial outcomes. On April 1, 2021, Q2 Solutions was acquired by IQVIA.
Missing: Q2 Solutions's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Q2 Solutions's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Q2 Solutions
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Q2 Solutions is included in 1 Expert Collection, including Cancer.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Latest Q2 Solutions News
Jan 25, 2023
Lyon, FRANCE New York, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Omics Lab Services Market Size, Share & Industry Trends Analysis Report By Business, By End Use, By Type, By Product, By Frequency of Service, By Regional Outlook and Forecast, 2022 - 2028" - https://www.reportlinker.com/p06412068/?utm_source=GNW The goal of functional genomics is to determine the functions of as many genes in a particular organism as feasible. Transcriptomics, proteomics, and saturated mutant collections are combined with other -omics approaches. The market for omics lab services is expanding as a result of factors including rising customer demand and acceptance of the services as well as rising company involvement. For instance, to speed up therapeutic target identification utilizing AI-based genomic analysis, Illumina, Inc., and AstraZeneca engaged in a strategic alliance in October 2022. Further study into the genetic susceptibility to certain illnesses has been made possible by the expansion of the genomic data pool as a result of research efforts. The clinical use of this data pool is anticipated to revolutionize the healthcare system by enabling the delivery of more precise, efficient, and dependable disease management solutions. The industrial and healthcare sectors are working to effectively integrate genetic data into clinical procedures, despite the fact that clinical usage of genomic data is still in its infancy. The creation of diagnostic tools based on omics research is still in its infancy. The challenge for developers in the next years will be to provide outcomes that are reliable and timely enough to show the clinical value of such tests. Such examples will be necessary to convince healthcare professionals to use the tests and convince other parties to pay for their costs. COVID-19 Impact Analysis Due to the COVID-19 pandemic, 2020 experienced unheard-of growth. A variety of cancer immunotherapies have been evaluated using advanced omics technologies, including single-cell omics, multi-omics, and conventional omics techniques. Additionally, the industry is being driven by the increasing use of "multi-omics" in research and the use of sophisticated sequencing platforms in the context of precision medicine. COVID-19 has significantly disrupted the pharmaceutical industry’s supply chain as a whole. In order to comprehend the COVID-19 virus, several small businesses have begun omics-based clinical studies. Market Growth Factors The Massive Investment of the Government for Genomics Projects Governments in a number of nations have made considerable investments in genomics in recent years. These government investments have aided the development of new technology significantly. For instance, The Department of Biotechnology (DBT) launched the "Genome India Project (GIP)" in January 2020. The goal of the initiative is to collect 10,000 genetic samples from Indian residents in order to create a reference genome. Precision health, rare genetic illnesses, the mutation spectrum of genetic and complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research are some of the areas of focus of this project. NGS Platforms’ On-going Technical Breakthroughs Continuous technical breakthroughs in sequencing methods have made it possible to create effective, portable, and user-friendly NGS systems with a shorter turnaround time and the ability to offer rapid and accurate findings. Leading corporations are increasing their R&D spending in order to strengthen their market positions and share since the launch of such items and technologies gives them an instant competitive advantage. Technical advancements have led to the addition of several new bioinformatics tools to metagenomics, increasing market revenue. Market Restraining Factors A Scarcity of Qualified Professionals Data from omics can be utilized for a wide number of purposes, such as pharmacogenomics, diagnostics, and toxicogenomics. In some circumstances, technical improvements have made it possible for the instruments in use to give an analysis; however, the reader’s interpretation is still up to them. It is vital to recruiting skilled professionals to evaluate and interpret the outcomes of sequencing data due to the intricacies involved and the requirement for an in-depth understanding of omics. Business Outlook Based on the business, the Omics Lab Services Market is divided into Hospitals, Research Institutes, and Diagnostic Labs. In 2021, Diagnostic Labs segment accounted for the largest revenue share in the market. The rise in testing and the accessibility of resources for conducting tests are responsible for the segment’s expansion. Improved hospital dependence on diagnostic labs for testing and assessment is contributing to the segment’s increased growth. End-Use Outlook Based on End-Use, the omics lab services market is categorized into Cancer, Pharmaco, Reproductive, Other Genetic Tests, Forensics, Population Studies, Skincare, Nutrition, Vitamins and Supplements, Genealogy, and Others. The reproductive segment acquired the considerable revenue share in the market in 2021. The study of oocytes (or the somatic cells surrounding them) and embryos, where the low quantity of material significantly decreases the information accessible when compared with somatic tissues, is the first clear area to profit from the capacity to amplify DNA (using PCR-type reactions). The number of unidentified genes discovered to be expressed in oocytes or cumulus cells as opposed to granulosa cells nowadays still reflects this. Type Outlook Based on type, the Omics Lab Services Market is classified into Genomics, Proteomics, Transcriptomic, Metabolomics, and Epigenetics. The epigenetics segment garnered the significant revenue share in the market during 2021. The future potential provided by the epigenetic analysis is responsible for the segment’s expansion. Businesses in the omics lab services market are concentrating on expanding their product and service portfolios for this market segment. For instance, Eisbach Bio and MD Anderson collaborated strategically to create a drug that targets epigenetics in cancer in January 2022. Product Outlook Based on product, the omics lab services market is classified into Hardware Equipment (Instrument, Kits, and Chips), Testing / Lab (Services), and Analytics / Interpretation (Personalization and Interpretation). The hardware equipment segment registered the highest share in the market in 2021. The instruments used in genomic applications are likely to get smaller, which will boost market expansion. Specificity, sensitivity, and automation are benefits provided by tiny devices in the development of point-of-care diagnostics. Frequency of Service Outlook Based on the frequency of service, the omics lab services market is classified into One-off, Repeat, and Continuous segments. In 2021, the continuous segment led the market for omics lab services. Genetic technologies are increasingly being used at all periods of life, including old age and the postmortem stage. The use of genetic technology in healthcare creates unique ethical issues that endanger existing therapeutic modalities. These challenges include the varying definitions of value for genetic information. Regional Outlook Based on geography, the Omics Lab Services Market is divided into North America, Europe, Asia Pacific, and LAMEA. Due to the high accuracy, specificity, and sensitivity of genetic testing, North America led the global omics lab services market in 2021, which may be ascribed to this region’s growing use of genetic testing. Market expansion is predicted to be fueled by the growing demand for genetic testing in clinical studies, including customized healthcare for diseases like diabetes and cancer. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Illumina, Inc., BGI Group, Q2 Solutions (IQVIA), Flomics Biotech, PhenoSwitch Bioscience Strategies Deployed in Omics Lab Services Market Nov-2022: Quest Diagnostics took over LabCare Plus, the outreach laboratory services business of Summa Health. Under this acquisition, Quest Diagnostics acquired selected assets of LabCare Plus. Moreover, Quest Diagnostics would widen access to insights and diagnostic innovations, empowering improved health for more communities in Northeastern Ohio. Feb-2022: PhenoSwitch Bioscience came into collaboration with Proteoform Scientific, a proteomics sample preparation technology developer, and manufacturer. Under this collaboration, PhenoSwitch Bioscience along with Proteoform would provide better value in data analytics, sample prep, and mass spec, combining all these important components in a flawless customer experience. Jan-2022: Illumina, Inc., partnered with SomaLogic, a company that works in data-driven proteomics technology. Under this partnership, Illumina would be able to develop and deploy NGS-based protein identification and measurement tools in laboratories internationally. Moreover, this would promote the expansion and use of high-plex protein pattern recognition tests. Apr-2021: Agilent Technologies took over Resolution Bioscience, the company engaged in the commercialization and development of next-generation sequencing (NGS)-based precision oncology solutions. The latter company’s liquid biopsy-based diagnostic technologies reinforced the former company’s portfolio to clinical diagnostics and biopharma customers and increased the growth opportunities of Agilent’s genomics and diagnostic business. Sep-2020: Qiagen NV took over NeuMoDx Molecular Inc., a molecular diagnostics company. Under this acquisition, Qiagen NV would enhance its portfolio of automated testing solutions and deliver another driver for future development. Moreover, the complete integration of Qiagen NV and NeuMoDx systems would allow Qiagen NV to handle laboratory requirements in any environment for molecular diagnostics. Jun-2020: Q2 Solutions partnered with Thermo Fisher Scientific, a provider of end-to-end drug development offering that includes Biologics, API, and viral vector services. Following this partnership, Q2 Solutions would use Ion Torrent Genexus System. Furthermore, adding the Ion Torrent Genexus System capabilities would enable Q2 Solutions to drastically decrease the time to provide clinical reports to trial sites, therefore helping patients access investigational drugs faster. Nov-2018: Quest Diagnostics completed the acquisition of the U.S. laboratory services business of Oxford Immunotec, a diagnostics company focused on commercializing and developing proprietary tests. Through this acquisition, Quest Diagnostics would buy and use T-SPOT.TB test kits and related accessories. Jan-2018: Agilent Technologies completed the acquisition of Luxcel Biosciences, a company focused on the productization and development of optical sensor technologies. The acquisition increased Agilent’s growth into Biopharma/Pharma discovery and in vitro toxicology-screening applications. Scope of the Study
Q2 Solutions Frequently Asked Questions (FAQ)
When was Q2 Solutions founded?
Q2 Solutions was founded in 2015.
Where is Q2 Solutions's headquarters?
Q2 Solutions's headquarters is located at 5827 South Miami Blvd., Morrisville.
What is Q2 Solutions's latest funding round?
Q2 Solutions's latest funding round is Acquired.
Who are the investors of Q2 Solutions?
Investors of Q2 Solutions include IQVIA.
Who are Q2 Solutions's competitors?
Competitors of Q2 Solutions include Ontada.
Compare Q2 Solutions to Competitors
nference makes biomedical knowledge computable to solve urgent healthcare problems of biopharmas and medical centers. The company offers EMR data, software products and services, record de-identification, curation of unstructured information, and data creation via digitization of pathology and molecular sequencing. It was founded in 2013 and is based in Cambridge, Massachusetts.
Semalytix offers pharmaceutical companies an AI-powered data tool to better understand real-world patient experiences. Its flagship product, dubbed "Pharos", is a patient research tool that pulls in and cleans up various unstructured public data -- such as blogs, forums, social media etc. -- and then applies algorithms to deliver real-time patient insights into unmet needs, treatment experience, and how severely a disease impacts the lives of those who suffer from it.
Holmusk builds an evidence platform with behavioral health combining behavioral health databases with AI-powered analytics and digital solutions. Its proprietary technology powers data-driven medicine that leverages analytic and digital tools to address the need in healthcare and pharma-life science. The company was founded in 2015 and is based in Singapore.
MediMergent is a data collection and analytics company focused on Real-World Data (RWD) and Real-World Evidence (RWE) related to patients’ health status. MediMergent has built and deployed a digital platform that collects RWD from customized patient surveys, medical records, health insurance claims and billing data, pharmacy prescriptions and refill data, and, where appropriate, information from wearable medical devices and apps. MediMergent combines this data, acquired directly from the patients, that relate to first-hand accounts of their perceived risk versus benefit relationship for select medications, to generate a unique set of data or evidence (RWE) related to improve outcomes and reduce costs of healthcare. Using proprietary algorithms, MediMergent produces data that can be used by the entire healthcare ecosystem including prescribers, pharmacists, health insurers, pharmaceutical companies, corporations, regulators and importantly, patients.
Komodo Health operates a healthcare insights platform that brings transparency and market intelligence to healthcare and life sciences. Its platform use tools and brings together data across enterprises, public domain, and proprietary sources, enabling healthcare and life science industries. The company was founded in 2014 and is based in San Francisco, California.
COTA provides healthcare services for cancer-affected patients. It combines its proprietary technology and analytics solutions to inform decisions and actions. COTA partners with life sciences companies to reveal insights to accelerate drug development and helps uncover previously unknown insights. The company was founded in 2011 and is based in Boston, Massachusetts.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.